NASDAQ: NBIXNeurocrine Biosciences Revenue
Neurocrine Biosciences revenue was $3.37B for the trailing 12 months ending Jun 30, 2026, with 102.6% growth year over year. Quarterly revenue for the quarter (Q2 2026) ending on Jun 30, 2026 was $959.0M, up 17.7% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, NBIX annual revenue was $2.9B, with 21.4% growth year-over-year.
NBIX past revenue growth
How has NBIX's revenue growth performed historically?
Company
34.42%
Industry
54.63%
Market
40.25%
NBIX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
NBIX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
NBIX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance
NBIX revenue history
Current Revenue
$3.4B
Current Earnings
$705.5M
Current Profit Margin
20.9%
Be the first to know when NBIX announces revenue.
NBIX Revenue History By Year
| NBIX Yearly Revenue | NBIX Revenue | NBIX Change | NBIX Revenue Growth |
|---|---|---|---|
| 2025-12-31 | $2.86B | $505.20M | +21.45% |
| 2024-12-31 | $2.36B | $468.20M | +24.81% |
| 2023-12-31 | $1.89B | $398.40M | +26.76% |
| 2022-12-31 | $1.49B | $355.20M | +31.34% |
| 2021-12-31 | $1.13B | $87.60M | +8.38% |
| 2020-12-31 | $1.05B | $257.80M | +32.71% |
| 2019-12-31 | $788.10M | $336.90M | +74.67% |
| 2018-12-31 | $451.20M | $289.57M | +179.16% |
| 2017-12-31 | $161.63M | $146.63M | +977.51% |
| 2016-12-31 | $15.00M | -$4.77M | -24.12% |
| 2015-12-31 | $19.77M | N/A | N/A |
| 2014-12-31 | $0.00 | -$2.92M | -100.00% |
| 2013-12-31 | $2.92M | -$50.22M | -94.51% |
| 2012-12-31 | $53.14M | -$24.27M | -31.36% |
| 2011-12-31 | $77.41M | $43.91M | +131.08% |
| 2010-12-31 | $33.50M | $30.55M | +1,034.47% |
| 2009-12-31 | $2.95M | -$1.02M | -25.71% |
| 2008-12-31 | $3.98M | $2.75M | +224.75% |
| 2007-12-31 | $1.22M | -$38.01M | -96.88% |
| 2006-12-31 | $39.23M | -$84.66M | -68.33% |
| 2005-12-31 | $123.89M | $38.71M | +45.45% |
| 2004-12-31 | $85.18M | -$53.90M | -38.76% |
| 2003-12-31 | $139.08M | $121.03M | +670.73% |
| 2002-12-31 | $18.05M | -$23.20M | -56.25% |
| 2001-12-31 | $41.24M | $26.65M | +182.71% |
| 2000-12-31 | $14.59M | -$2.20M | -13.12% |
| 1999-12-31 | $16.79M | $754.00k | +4.70% |
| 1998-12-31 | $16.04M | -$10.11M | -38.66% |
| 1997-12-31 | $26.14M | $6.93M | +36.05% |
| 1996-12-31 | $19.22M | $13.11M | +214.72% |
| 1995-12-31 | $6.11M | $5.94M | +3,679.88% |
| 1994-12-31 | $161.53k | N/A | N/A |
| 1993-12-31 | $0.00 | N/A | N/A |
Neurocrine Biosciences Revenue FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.